Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.1K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.1K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

1.4K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
1.4K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.

Blood advances·2026
Same author

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial.

Cancers·2026
Same author

A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.

Blood advances·2025
Same author

Lymphoma Therapy Response Assessment with Low-Dose [<sup>18</sup>F]FDG Total-Body PET/CT.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025
Same author

Light chain crystalline podocytopathy caused by electron-lucent crystals - a diagnostic challenge: a case report.

Ultrastructural pathology·2025
Same author

Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

相关实验视频

Updated: Jul 11, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K

在血液性恶性瘤中检查点抑制.

Aaron Tsumura1, Daniel Levis2, Joseph M Tuscano1,2

  • 1Division of Malignant Hematology/Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA, United States.

Frontiers in oncology
|November 3, 2023
PubMed
概括

针对CTLA-4和PD-1/PD-L1通路的免疫检查点抑制剂在血液恶性瘤,特别是霍奇金淋巴瘤中表现有前途. 对于高风险髓状腺癌,如抗CD47封锁等新型目标正在出现.

关键词:
现场行动组-3这是一个紧张的紧张.cd47cd47cd47cd47cd47cd47cd47cd47cd47cd47cd47cd47cd47cd47cd47c检查点抑制剂检查点抑制剂血液学恶性瘤 血液学恶性瘤免疫疗法 免疫疗法这种白血病是白血病.淋巴瘤淋巴瘤是什么

更多相关视频

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.1K
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

20.2K

相关实验视频

Last Updated: Jul 11, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.1K
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

20.2K

科学领域:

  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学
  • 血液学 血液学 血液学

背景情况:

  • 检查点抑制剂治疗,包括针对CTLA-4和PD-1/PD-L1的单克隆抗体,已经彻底改变了癌症治疗,特别是在固体瘤中.
  • 虽然霍奇金淋巴瘤已经显示出显著的临床益处,检查点抑制在其他血液恶性瘤的应用正在扩大,特别是在复发/耐药设置.

研究的目的:

  • 在过去十年中,回顾最近的发展和免疫检查点抑制血液恶性瘤的进展.
  • 突出检查点抑制剂的新兴治疗目标和协同应用.

主要方法:

  • 审查最近的科学文献和关于免疫检查点抑制剂在血液恶性瘤的临床数据.
  • 对FDA批准的单克隆抗体药物和新检查点路径目标的分析.

主要成果:

  • 检查点抑制剂已在霍奇金淋巴瘤中表现出有效性,并且在其他血液恶性瘤中表现出实用性,特别是在复发/耐药病例中.
  • 检查点抑制可以与其他疗法 (如造血干细胞移植) 协同作用.
  • 新兴的标,如抗CD47阻断,对高风险的骨髓质疏松综合征和TP-53突变性急性髓性白血病有希望.

结论:

  • 在利用免疫检查点抑制用于血液性恶性瘤方面取得了重大进展.
  • 进一步的研究对于优化这些药物的使用和探索新的治疗策略至关重要.